- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Wayne Today
By the People, for the People
Teleflex Outlines Major Portfolio Transition
Company to divest Acute Care, Interventional Urology, and OEM businesses, focus on core RemainCo operations
Published on Mar. 3, 2026
Got story updates? Submit your updates here. ›
Teleflex (NYSE:TFX) announced plans for a major portfolio transition, including the divestiture of its Acute Care, Interventional Urology, and OEM businesses. The company will focus on its core 'RemainCo' operations, which will include the recently acquired BIOTRONIK Vascular Intervention business. Teleflex also provided an updated financial framework, including guidance for 2026 that factors in stranded costs and increased R&D investment.
Why it matters
Teleflex's strategic shift represents a significant restructuring as the company looks to streamline its operations and focus on high-growth, high-margin product segments. The divestitures are expected to provide substantial cash proceeds that Teleflex plans to use for share buybacks and debt reduction, potentially enhancing shareholder value. However, the transition will also result in near-term challenges, including stranded costs and the need to integrate the BIOTRONIK acquisition.
The details
Teleflex outlined plans to sell its Acute Care, Interventional Urology, and OEM businesses for total cash proceeds of $2.03 billion. The company expects the divestitures to close in the second half of 2026, subject to regulatory and other conditions. Management also discussed the integration of the recently acquired BIOTRONIK Vascular Intervention business, increased R&D investment expectations, and a 2026 outlook shaped by separation-related stranded costs.
- Teleflex signed definitive agreements to sell the three businesses in 2026.
- The divestitures are expected to close in the second half of 2026.
The players
Teleflex
A diversified global provider of medical technologies, specializing in critical care and surgery.
Stuart Randle
Interim President and CEO of Teleflex.
John Deren
CFO of Teleflex.
BIOTRONIK
A medical device company that Teleflex recently acquired.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
Teleflex's strategic shift represents a significant restructuring as the company looks to streamline its operations and focus on high-growth, high-margin product segments. The divestitures are expected to provide substantial cash proceeds that Teleflex plans to use for share buybacks and debt reduction, potentially enhancing shareholder value.
